SPCs are an intellectual property right that grants an extension of up to 5 years on a 20-year patent term for an innovative pharmaceutical. The goal of the SPC is to offset the loss of patent protection that occurs during the development and clinical trials of a generic or biosimilar.
The European Commission has launched a public consultation on supplementary protection certificates (SPCs) and patent research exemptions. Changes to the ways in which SPCs are administered in the European Union could have a significant impact on the biosimilars marketplace.
SPCs are an intellectual property right that grants an extension of up to 5 years on a 20-year patent term for an innovative pharmaceutical. The goal of the SPC is to offset the loss of patent protection that occurs during the development and clinical trials of a generic or biosimilar.
Bolar patent exemptions, which are intended to speed market entry of generic therapies, provide exemptions to patent protection, even in cases in which SPCs are in force. These exemptions state that some pre-market activities cannot be regarded as infringements of a patent or SPC.
However, Martin Dræbye Gantzhorn and Emil Bjerrum, both of Denmark law firm Bech-Bruun, explain that because SPCs are granted and enforced at a national level, rather than at an EU level, confusion about, and difficulties with, these certificates and their related bolar exemptions are widespread.
For example, in some EU member states, bolar exemptions do not permit access to active pharmaceutical ingredients for the purpose of biosimilar development. In other states, it is not clear in the local law whether exemptions may be used for activities related to marketing drugs. Gantzhorn and Bjerrum also point out that bolar exemptions have been subject to stakeholder questioning insofar as they may disadvantage EU manufacturers; if EU drug makers are not allowed to produce pharmaceuticals for the non-EU market during the SPC term, developers located outside the EU will have an advantage in gaining early market share in these nations.
SPCs have also been subject to question in the biosimilars context due to the nature of biosimilar therapies themselves; SPCs cover the active ingredient or combination of active ingredients in a product. Because biosimilars are, by definition, only highly similar to their references, there remains some question as to whether SPCs can be applied to forestall biosimilar development. This question has been highlighted in Norway, where the judicial system first determined that SPCs did not apply to follow-on biologics, then overturned the decision in an appellate court.
The new consultation is intended to gain feedback from stakeholders in order to determine whether the Commission should take further legislative action concerning the certificates and waivers. Responses will be collected via online questionnaire, and results will be published by the Commission.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.